A recent trial has revealed excessive toxicity, however, in patients receiving a combination of erlotinib (an oral EGFR tyrosine kinase inhibitor) and the standard FOLFIRI chemotherapy regimen.

Neutropenia is a common adverse effect of cytotoxic chemotherapy ... Data indicate that other toxicities are worse in the presence of febrile neutropenia and that these concurrent events may ...

Using a gene-screening method, Stanford Medicine researchers have uncovered why chemotherapy can damage heart cells and have ...

Chemotherapy-induced neutropenia is a major risk factor for infection-related morbidity and mortality and an important dose-limiting toxicity in cancer treatment. The incidence of severe ...

Chemotherapy targets cancer cells by disrupting DNA replication and mitotic processes, despite side effects on healthy cells.

29 Patients were encouraged to keep a written note of any toxicity symptoms experienced during the week before the evaluation interview. One week after each cycle of chemotherapy and 1 week before the ...

Toxicity ≥3 or ≥2 according to CTCAE v2.0 Decreased risk of toxicity for the haplotype 677C-1298C in 5-FU + RT-treated patients Higher risk of diarrhea and mucositis in AA homozygotes treated ...

Sometimes, the drug dose will need to be reduced, or even stopped altogether. There is now a blood test to identify an uncommon DNA gene change that can lead some patients to experience greater ...

ADC Therapeutics, Sutro Biopharma and Zai Lab are among those developing antibody-drug conjugates to address payload and ...

During a Case-Based Roundtable® event, Patrick M. Forde, MD, discussed safety and tolerability concerns with immunotherapy in ...